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Summary 
Clonal activation of CD4 + and CD8 + T  lymphocytes depends on binding of peptide-major 
histocompatibility complex (MHC) molecule complexes by their oe/3 receptors, eventually resulting 
in sufficient aggregation to initiate second messenger generation. The nature of intraceUular signals 
resulting from such T cell receptor (TCR) occupancy is believed to be independent of the specific 
structure  of the ligand being bound,  and to vary quantitatively,  not qualitatively,  with  the 
concentration of ligand offered and the af~nity of the receptor for the peptide-MHC molecule 
complex. In contrast to the expectations of this model, the analysis of the response of a T helper 
type 1 clone to mutant EoeE3 k molecules in the absence or presence of a peptide antigen revealed 
that peptide inhibited the interleukin 2 (IL-2) response to an otherwise allostimulatory mutant 
form of this MHC class II molecule. The inhibition was not due to competition for formation 
of alloantigen, it required TCR. recognition of peptide-mutant MHC molecule complexes, and 
it decreased IL-2 production without affecting receptor-dependent IL-3, IL-2 receptor oe, or size 
enlargement responses. This preferential reduction in ILo2 secretion could be correlated with the 
costimulatory signal dependence of this cytokine response, but could not be overcome by crosslinking 
the CD28 molecule on the T  cell. These results define a new class of TCR. ligands with mixed 
agonist/antagonist properties, and point to a ligand-related variation in the quality of clonotypic 
receptor signaling events or their integration with other signaling processes. It was also found 
that a single TCR. ligand showed greatly different dose thresholds for the elicitation of distinct 
effector responses from a cloned T cell population. The observations that changes in ligand structure 
can result in qualitative alterations in the effects of receptor occupancy and that quantitative variations 
in ligand density can be translated into qualitative differences in T cell responses have important 
implications for models of intrathymic selection and control of the results of active immunization. 
h2 antigen specificity of T lymphocyte responses resides 
the  recognition  properties  of clonally distributed, 
Ig-like TCRs. For CD8 + and CD4 + T  cells, the physiolog- 
ical ligand for the clonotypic c~/3 receptors (TCR) on these 
cells consists of a peptide bound to the polymorphic region 
of plasma membrane-associated MHC class I or II molecules, 
respectively (1, 2). Signals essential to T  cell triggering are 
elicited through the c~/3 receptor as a consequence of its in- 
teractions with other proteins having the capacity to generate 
intracellular second messengers (3). Recent data indicate that 
the CD3 % ~, e:~'/~ complex stably associated with the TCR 
ce/3  consists  of  a  minimum  of  two  signal  transduction 
modules with distinct and independent capacities to initiate 
second messenger cascades (4, 5) that include primary events 
such as tyrosine phosphorylation (6)  and secondary events 
such as phosphoinositol bis-phosphate (PIP2) hydrolysis and 
elevation of [Ca  2+]i (7,  8). 
The effect of these biochemical events on T cell differenti- 
ation is heavily influenced by other receptor-ligand interac- 
tions generating  signals  differing qualitatively from those 
evoked by TCK-ligand interaction (9-13). The participation 
of such costimulatory signals is most evident in control of 
production of IL-2 (14), the cytokine principally responsible 
for the clonal expansion that follows T cell activation. Meta- 
bolically inactivated cells bearing recognizable ligands for 
TCR.s on CD4 + cells are poor or ineffective stimulators of 
Ib2-dependent T cell proliferation (15-17). The component 
missing in such circumstances contributes to T cell IL-2 produc- 
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cupancy and TCR-regulated second messenger generation (18). 
Several candidate receptor-ligand pairs  have been proposed 
as the source of this critical "second signal" but many studies 
have failed to distinguish molecular interactions contributing 
to receptor occupancy by augmenting cell-cell adhesion from 
those providing a unique second signal in the face of ade- 
quate receptor occupancy,  without which I1:2 production 
and clonal expansion does not occur (19). When analyzed 
in this manner, the binding of B7 on the APC by CD28 on 
the responding T cell (11-13, 20-22) and the recognition of 
the heat-stable antigen (19, 23) on APC by an uncharacter- 
ized T cell counter-receptor appear to be the best candidates 
for  providing the  costimulatory signal(s)  needed for I1:2 
production. 
Despite the complex biochemical events associated with 
TCR-dependent intraceUular  signaling, a relatively simple 
model for the relationship between peptide-MHC ligand and 
TCR in the initiation of T  cell triggering remains the pri- 
mary paradigm in the field (24, 25).  Activation is generally 
believed  to occur when an adequate number of TCRs are 
aggregated at the adhesion receptor-generated membrane in- 
terface between the T cell and the presenting cell (26). The 
extent of this receptor-ligand aggregation depends on the 
number of available receptors  on the T cell, the number of 
available  peptide-MHC  complexes  on  the APC,  and  the 
affinity of the TCR for the ligand. It is commonly assumed 
that when a high level of MHC-peptide complexes  on the 
APC fails to induce measurable T cell activation, this is due 
to a low affinity of the TCR for the ligand that prevents 
receptor occupancy from exceeding the threshold needed for 
second messenger generation within the T  cell itself (27). 
This affinity-based occupancy model predicts that in the 
presence  of intact, metabolically active APC known to be 
capable  of delivering costimulatory signals,  peptide-MHC 
complexes should fall into two categories:  agonists that can 
induce full T cell activation and nonagonists that are ignored 
by the T cell because even at saturation of the surface MHC 
molecules with peptide antigen, the number of occupied TCR 
is below the triggering threshold, due to a low TCR affinity 
for the peptide-MHC complex (24). However, the recent work 
of Evavold and Allen (28)  has cast into doubt the validity 
of this simple occupancy model for T  cell activation. They 
observed that a single residue substitution in the peptide ligand 
for the TCR on a mouse Th2 clone prevented stimulation 
of proliferative responses,  while permitting I1:4  cytokine 
production. This indicates that a ligand can stimulate T cell 
second messenger generation without evoking the full reper- 
toire of effector responses. We report here the ability of cer- 
tain peptide-MHC complexes interacting with the TCR to 
actively and selectively block IL-2 production by a mouse Thl 
clone,  without preventing 11:3 secretion, I1:2Ro~ upregula- 
tion, or cell size enlargement induced by an available TCR 
agonist. Our studies demonstrate that this effect does not 
result from competition for receptor occupancy,  but rather 
is related to alteration in the quality of T cell signaling that 
may interfere with the development of, or response to, costimu- 
lation. These results define a new class of receptor ligands 
with the properties of mixed agonists/antagonists  able to selec- 
tively modulate certain T  cell effector activities  in a TCR- 
specific manner. These same studies also showed that the oc- 
cupancy thresholds for secretion of distinct cytokines can vary 
markedly using a single ligand-TCR combination, and that 
the difference appears to reflect an unequal contribution of 
costimulatory signals to the development of specific effector 
responses. These results have important implications for models 
of thymic selection and peripheral T cell activation, and they 
may provide new pharmacological approaches  to the treat- 
ment of autoimmune disease and in vaccine design. 
Materials  and Methods 
eDNA Constructs and L  Cell Transfectants.  cDNA expression con- 
structs encoding wild-type and mutant E3  k chains were created 
as previously  described (29). These plasmids were cotransfected  into 
the DAP.3 subline of mouse L cells (30) together with a construct 
encoding wild-type Eot and a plasmid containing a marker gene 
for drug selection. Drug-resistant clones expressing suitable sur- 
face levels of Ec~E~ dimers were isolated as described (29). 
Peptides.  The CNBr fragment 81-104 from pigeon cytochrome c 
(PCC 81-104)  1 was prepared as previously described (31). DASP, 
an analogue of moth cytochrome c (residues 86-90 and 94-103; 
KKANELIAYLKQATK),  as well as PCC 88-104, hen egg lyso- 
zyme (HEL) 81-96, and HEL 46-61 with or without an NH2- 
terminal long-chain biotin (32) were synthesized and purified by 
Dr. John Coligan (Biological Resources Branch, NIAID,  NIH, 
Bethesda, MD). DASP conjugated to an NHrterminal long-chain 
biotin was prepared and kindly donated by Dr. Jonathan Rothbard 
(ImmuLogic Corp., Palo Alto, CA). PCC 81-104 [99Q] was the 
kind gift of Dr. Ronald Schwartz, (LCMI, NIAID, NIH). 
T  Cell Clones and Hybridomas.  The 3C6 CD4 + T cell clone 
was produced as previously  described (33) from pigeon cytochrome 
c-immune spleen cells of a B10.A mouse. The C6E1 CD4 § T cell 
hybridoma was produced from the 3C6 clone by fusion to BW1100 
(34), which lacks its own functionally rearranged TCR cr  and 3 
gene loci. The hybridoma  and the T cell  clone were grown in RPMI 
1640 with 10% FCS, 2 mM glutamine, and nonessential amino 
acids. The 3C6 cytochrome c-specific T cell clone was maintained 
in vitro by stimulation with antigen and irradiated spleen cells, 
followed by a period of rest in the absence of antigen. Cells col- 
lected at the end of the resting phase were centrifuged over a Ficoll 
gradient and treated with a cocktail of I-A- and l-E-specific mAbs. 
Antibody-treated T cells were negatively selected  by sorting with 
magnetic beads (Dynal, Inc., Great Neck, NY) and an MPC-1 mag- 
netic concentrator as recommended by the supplier. 
T Cell FunctionaI Assays.  Production  of  I1:2 and Ib3 in response 
to L cell transfectants in the presence or absence of added peptide 
was measured as previously described (35). In brief, 2-5  x  104 T 
cells were incubated with 2-5  x  104 transfected L cells in the 
wells of 96-well flat-bottomed culture plates in 200/zl of complete 
medium with or without various  concentrations  of  peptide antigen. 
Supernatants were collected after 24 h and assayed  for I1:2 content 
using CTLL indicator cells or for I1:3 content using FDC.1 cells. 
I1:2 and IL-3 units were calculated as the inverse of the dilution 
giving 50%  of the  maximum  [3H]thymidine incorporation by 
CTLL (I1:2) or FDC.1 (I1:3) cells observed with reference II:2 
1 Abbreviations used in this paper: HEL, hen egg lysozyme;  PCC, pigeon 
cytochrome  c; SSC, side scatter. 
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sessing [3H]thymidine incorporation between 48 and 66 h of cul- 
ture. For experiments in which the data are expressed as "percent 
max" or "percent alloresponse;' the actual absolute 100% responses 
were: IL-2 alloresponse, 10-40 U/m/; IL-3 alloresponse, 100-500 
U/ml; IL-2  response to Ec~EB  k plus PCC peptide, 150-300 U/ml; 
IL-3 response to Ec~EB  k plus PCC peptide,  1,000-10,000 U/ml; 
IL-2 response to fixed cells bearing  Ec~E~  k plus PCC peptide, 
30-50 U/ml; IL-3  response to fixed cells bearing EotEB  k plus PCC 
peptide,  50-200  U/ml. 
For analysis of the effects on anti-CD28  antibody on the 3C6 
response, 5  ￿  104 3C6 T  cells were cocultured with 5  ￿  104 
transfected  L cells expressing  the allostimulatory  mutant EccE/~  mol- 
ecule in the presence or absence of varying dilutions (1:250-16,000) 
of ascites containing hamster anti-mouse CD28 mAb (36). IL-2 
and IL-3 accumulation in these cultures was measured as described 
above. Where indicated, the anti-CD28  was crosslinked by first 
preincubating the 3C6 cells with the anti-CD28 for 1 h at 4~ 
washing  and then adding polyclonal anti-hamster  IgG antisera 
(Caltag Labs, San Francisco, CA) to a final dilution  of 1:40, in- 
cubating  for 1 h at 4~  then washing the cells before use in a 
standard stimulation  culture. 
Flow Cytometric Analysis.  Analysis  of  cell surface class II MHC 
molecule expression by transfected cells was carried out using the 
anti-Eot mAb 14.4.4S (37) and FITC goat anti-mouse F(ab')2 as 
the detection reagent  (38). Cells were analyzed using either an 
EPICS V (Coulter Electronics, Hialeah, FL), FACSAnalyzer  |  or 
FACScan  (Becton Dickinson & Co., Mountain View, CA). For 
muttiparameter analysis of 3C6 T cells incubated with APC with 
or without PCC peptide, 3C6 cells (0.5  x  10  s) were cocultured 
with FT 27.2.A2 1-E-expressing  L cells (0.5  x  10  s) that had been 
preincubated for I h at 37~  with PCC 81-104 peptide (20 gM). 
After 24 h of incubation,  cells recovered from the 48-well plate 
were stained using an anti-Thy-l,2 mAb labeled with FITC (Becton 
Dickinson & Co.) and mAb 7D4, an anti-IL2-Rc~-specific  reagent 
(39). Detection of  bound 7D4 was with R-PE-labeled goat anti-rat 
antibody (Caltag Labs). Cells were analyzed on a FACScan  |  flow 
cytometer. Cells were gated on Thy-l.2 staining, and positive cells 
(3C6 T cells) were analyzed for 7D4 expression and cell size (side- 
scatter [SSC] parameter). Supernatants of these cultures were as- 
sayed for Ib2 and IL-3 content. Parallel cultures were analyzed for 
[3Hlthymidine incorporation. 
Measurement of Peptide Binding Using Biotinylated Peptides.  A 
modified version of the assay of Busch et al. (32) was used to mea- 
sure peptide binding to cell-associated class II MHC molecules. 
After extensive washing in PBS/I% BSA, 2  x  105 DAP.3 cells 
or DAP.3 transfectants expressing various Ec~E/3 molecules were 
incubated at 37~  in 200 #1 of PBS/2% FCS containing the indi- 
cated concentration of  biotinylated peptide. In the competition ex- 
periments competitors were added at the same time as labeled pep- 
tide and at the indicated concentrations. After 4 h, the cells were 
washed and stained with a sandwich of  FITC-avidin (Vector  Labora- 
tories,  Inc.,  Burlingame,  CA),  biotinylated  antiavidin  (Vector 
Laboratories, Inc.), and FITC-avidin (Vector Laboratories, Inc.). 
After washing, the cells were analyzed on a FACScan  |  flow cytom- 
eter for fluorescence. Only viable cells were considered in the anal- 
ysis, as determined by propidium iodide (PI) staining. The data 
are expressed as net mean fluorescence intensity (MFI), calculated 
as: actual MFI minus MFI obtained by staining in the absence of 
biotinylated peptide. Percent inhibition in the competition experi- 
ments was calculated as: 100x  (net MFI without competitor - 
net MFI with competitor/net MFI without competitor). 
Measurement ofCytokine mRNA Levels.  3C6 T cells were cocul- 
tured with FT 27.2.A2 cells expressing the allostimulatory mu- 
tant E~EB class II molecule that had previously been incubated 
with PCC 81-104 peptide for 1 h at 37~  After 4 h of coculture, 
total RNA was extracted by the guanidinium thiocyanate-phenol- 
chloroform method (40), analyzed on a denaturating agarose gel, 
and quantified spectrophotometricaUy.  Reverse  transcription of 1 gg 
of total RNA with 37.5 gg/ml of oligo(dT)lz-ls (Collaborative 
Research, Lexington, MA) was performed for I h at 42~  using 
600 U of Moloney routine leukemia virus (M-MLV) reverse tran- 
scriptase (GIBCO BRL, Gaithersburg, MD) in 50 mM Tris-HCl, 
pH 8.3, 3 mM MgC12, 60 mM KC1, 10 mM DDT, 75 gg/ml of 
acetylated  BSA, 1 U/ml of  RNasin (Promega Biotec, Madison, WI), 
and 1 mM of dATP, dGTP, dCTP, and dTTP. 1 gCi of [32P]dCTP 
(3,000 gCi/mM; Amersham Corp., Arlington Heights,  IL) was 
added in the reaction mixture.  The efficiency  of the reverse tran- 
scription reaction was assayed  by comparing the TCA-precipitable 
radiolabeled cDNA present in each sample. PCR analysis was per- 
formed on cDNA samples adjusted to contain the same amounts 
of TCA-precipitable labeled material. 10% of the product cDNA 
was combined with 1/~M of  each of the specific  Ib2 and Ib3 primers 
(Cytokine Mapping AmplimersTS;  Clontech Laboratories,  Inc., Polo 
Alto, CA), 200 #M of each dNTP, and 1.25 U ofTaq DNA poly- 
merase (5 U/ml; Perkin Cetus) in lx  PCR buffer (10 mM Tris- 
HC1, pH 8.3, 50 mM KCt, 2.5 mM MgC12, 100 gg/ml BSA). 
Total volume was 50 #1. PCRs were performed as described in the 
Cytokine Mapping Amplimers  TM manual (Clontech). The number 
of cycles was adjusted to fall in the log linear range of signal for 
these amplimers and cDNA source. PCR products were analyzed 
on 5% polyacrylamide precast Tris-Borate-EDTA gels (Bio-Rad 
Laboratories, Richmond, CA). Gels were dried and radiolabeled 
bands were quantified using a Phosphor-Imager  (Molecular Dy- 
namics, Inc., Sunnyvale, CA).  Images were analyzed by Image 
Quant  TM  version 3.15 so'ware (Molecular Dynamics, Inc.). 
Results 
Peptide Inhibition of the IL-2 Response of a T  Cell Clone to 
a Mutant MHC Class II Molecule.  3C6 is a Thl-type (41) 
cloned cell line derived from a PCC-immunized B10.A mouse 
that produces IL-2 when stimulated by antigen and splenic 
APC. In addition to the expected specific activation of 3C6 
by COOH-terminal cytochrome peptides presented by cells 
expressing the wild-type, self EotE~  k MHC class II mole- 
cule, this clone also responds in the absence of added antigen 
to APC expressing the closely related EotEB  ~  molecule. This 
constitutes an alloantigenic crossreaction that has been ob- 
served among such cytochrome c-reactive T cells (33). Tram- 
fected L cells expressing MHC class II molecules with mu- 
tant E/3  k proteins containing various EB  ~ aUelic substitutions 
were produced to examine the relationships among MHC 
molecule structure,  peptide  antigen  presentation,  and  al- 
lorecognition (29). Transfectants expressing molecules with 
E~/chains containing substitutions of E s allelic residues at 
positions 75 and 79 in the putative helix of the peptide-binding 
regions (referred to as B75  ~, 79  s) or at positions 72, 75, and 
79 evoked a substantial peptide-independent (alloantigenic) 
response (Fig.  1 A). 
3C6 was then tested for responses to PCC peptide presented 
by the mutant molecules capable of stimulating an alloanti- 
genic response. In addition to inducing a peptide-independent 
alloresponse, a clear dose-dependent stimulation of the clone 
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Figure  1.  Response of the 3C6 
Thl clone to PCC 81-104 peptide 
presented by E~E~ molecules mu- 
tated in the BHV3 region. (A) Ib2 
responses (alloreaetivity) of 3C6 to 
EccEB  k molecules with HV3 mu- 
tations  in  the  absence of  PCC 
81-I04 antigen.  (B) Effect of addi- 
tion of PCC 81-104 peptide on the 
3C6 Ib2 response to E~E~ mole- 
cules  with  B72s,75~,79  ~ (SSS) or 
~75s,79 , (KSS) ~  chains. 
by PCC peptide was observed using APC expressing an E3  k 
chain with s residues at positions 72, 75, and 79 (Fig.  1 B). 
Unexpectedly, addition of the same peptide to cells expressing 
a mutant EotE/3  k molecule with 375 s, 79 ~  not only failed to 
stimulate a response above that seen in the absence of pep- 
tide, but such peptide addition inhibited the IL-2 response 
in a dose-dependent fashion (Fig.  1 B). 
Competition for MHC Peptide-Binding Does Not Account for 
the PCC Peptide Inhibition of  Alloreactivity.  There is now sub- 
stantial evidence that many T cell responses to allogeneic MHC 
molecules involve recognition of the peptide(s) bound to the 
non-self MHC molecules (42-45).  Thus, a simple explana- 
tion for the ability of the PCC peptide to inhibit the 3C6 
alloresponse to  the/375 s,  79  ~ mutant  molecule would be 
competition for MHC class II molecule binding of a peptide 
necessary for the formation of the alloantigenic ligand rec- 
ognized by the 3C6 receptor. Such competition at the level 
of the MHC molecule has been suggested as an explanation 
for previous observations of exogenous peptide inhibition of 
allogeneic stimulation (46-48). This possibility seemed un- 
likely to us, however, as it is generally difficult to block MHC- 
dependent responses by addition of competing peptide after 
the stimulatory peptide has had an opportunity to bind (49, 
50). If the culture medium or the transfectant itself were the 
source of any putative peptide needed for the allostimulation, 
the continuously cultured cells would have had ample time 
to form the stimulatory peptide-MHC complexes before the 
introduction  of the  potentially competing PCC  peptide. 
Nevertheless, this possibility was directly assessed  by examining 
the effects on 3C6 alloresponses of other peptides able to bind 
to the mutant EotEB molecule to a similar extent as the in- 
hibitory PCC 81-104 peptide (Fig. 2 A). Fig. 2 B shows that 
despite only minor differences in direct MHC molecule bind- 
ing by three cytochrome-related peptides, they varied over 
two to three orders of magnitude in their ability to stimulate 
the 3C6 clone when presented by the wild-type EotE3  k mol- 
ecule. These data confirm the assignment of position 99 as 
a key epitopic residue in the PCC determinant (51-53), and 
show that the change at this position from lysine to gluta- 
mine affects TCR-dependent recognition, not MHC mole- 
cule binding. Fig. 2 C demonstrates that the ability of these 
same peptides to mediate inhibition of the 3C6 alloresponse 
to the/~75  s, 79  s mutant was directly related to their capacity 
to stimulate the clone in the context of the wild-type EotEB  k 
molecule. Thus, the fine specificity of the 3C6 TCR for the 
peptide, and not the ability of the peptide to bind to the mu- 
tant MHC molecule, clearly dictated the capacity to mediate 
inhibition of aUoantigen-stimulated IL-2 responses. This argues 
against direct peptide competition at the MHC molecule level 
as the cause of IL-2 response inhibition by PCC 81-104. Fur- 
ther evidence for this conclusion comes from similar experi- 
ments using an unrelated HEL peptide. Although it bound 
well to the mutant EotE/3 molecule (Fig.  3 A), this peptide 
also lacked the ability to inhibit alloantigen-driven IL-2 produc- 
tion by 3C6  (Fig.  3 B). 
Peptide Inhibition  Is  Not  Due  to  High-Dose  Suppression. 
Mouse Thl clones like 3C6 exhibit a characteristic decline 
in antigen-stimulated proliferation as the concentration of 
offered antigen  is  increased to  high levels  (24,  54).  This 
phenomenon is termed "high-dose suppression" and appears 
to be related to prolonged or repetitive TCR engagement. 
It was thus formally possible that the low apparent response 
of 3C6 to the mutant EotEB molecule was in fact due to a 
very high level of allostimulation, and that additional TCR 
ligand in the form of PCC peptide-MHC complexes drove 
the response even lower. 3C6 did exhibit high-dose suppres- 
sion when stimulated with wild-type EotEO  k plus PCC pep- 
tide (Fig. 4 A). However, the pattern observed was a reduced 
proliferative response in the face of increasing IL-2 cytokine 
accumulation in the culture. The inhibitory effect of PCC 
peptide  on 3C6  in  the presence of alloantigen  showed a 
different phenotype (Fig. 4 B). Added PCC peptide decreased 
IL-2 accumulation with only marginal effects on prolifera- 
tion. Consistent with these data, addition of small amounts 
of anti-Ec~E~ mAb to cultures of 3C6 stimulated in the ab- 
sence of PCC peptide did not result in augmentation of Ib2 
production (not shown). Such an increase would have been 
expected if the alloresponse were in the high-dose suppres- 
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Figure 2.  The inhibitory effect of E~E/~-binding peptides on 3C6 al- 
loresponses to the ~75s,79  ~  E/~-expressing transfectant is related to their 
ability to be recognized by the 3C6 receptor. (A) Binding of PCC 81-104, 
PCC 81-104 (99Q), DASP, and HEL 46-61 peptides to transfected L cells 
expressing Ec~EB molecules containing the/~75~,79  ~  E/~ chain as assayed 
by competition for the binding of biotinylated-DASP (25/xM).  Data are 
expressed as percent inhibition at each competitor  concentration,  calcu- 
lated as described in Materials and Methods￿9 (B) IL-2 response of 3C6 to 
PCC 81-104, PCC 81-104 (99Q),  and DASP peptides presented by an 
L cell transfectant expressing wild-type EctEB  k molecules. (C) Effect of 
PCC 81-104, PCC 81-104 (99Q), and ]:)ASP  peptides on IL-2 production 
induced by an L cell transfectant expressing the 375~,79  ~  E3 chain. Data 
are expressed as percent of IL-2 production obtained in the absence of any 
cytochrome c peptide in the culture￿9 
sion range, because of the reduction in receptor engagement 
caused by antibody addition. Thus, we conclude that the in- 
hibitory  effect  of peptide is  not  due  to  excessive TCR- 
dependent stimulation of 3C6. 
Inhibition Is Selective  for IL 2 Production and Does Not Involve 
Abrogation of All TCR-dependent Signaling.  Additional ex- 
periments were performed to determine if any effective TCR- 
dependent signal transduction occurred when 3C6 was ex- 
posed to alloantigen plus PCC peptide. As shown in the flow 
cytometry profiles of Fig. 5 A and summarized quantitatively 
in Fig. 5 B, under conditions of PCC peptide addition that 
blocked  virtually  all  I1.-2 accumulation  in  the  culture, 
alloantigen-stimulated, TCR-dependent IL-3 production, IL- 
2Rol chain upregulation, and cell size enlargement proceeded 
as they did in the absence of added PCC peptide. Thus, 3C6 
continued to receive biologically active signals through the 
TCR under the same conditions that abrogated the IL-2 re- 
sponse. This indicates that the activity of PCC-mutant Ec~E~ 
complexes in downregulating the IL-2 response did not re- 
sult from the elimination of effective TCR occupancy by the 
agonist alloantigen. The inability of a cytochrome-unrelated 
I-E binding peptide like HEL to affect either IL-2 (Fig. 3) 
or IL-3 (not shown) also indicates  that the divergent effect 
of PCC on IL-2 vs. IL-3 is not the result of replacing the al- 
loantigen agonist with a new ligand capable of only IL-3 stim- 
ulation. If this were the case, addition of the HEL peptide 
should have resulted in loss of both responses,  rather than 
the observed lack of any effect on cytokine production. Fig. 
5, C and D, demonstrates that the decrease in IL-2 measured 
in the inhibited cultures was not the result of increased IL-2 
consumption by proliferating cells, but reflected a decrease 
in steady-state IL-2 mRNA levels. IL-3 mRNA levels were 
similar in the presence or absence of added PCC peptide, as 
expected from the bioassays of II_,3 activity. 
Different Antigen Dose Thresholds  for IL2 vs. IL-3 Responses 
Based on  Varying Synergy between Costimulatory and  TCR 
Signals.  Neither inhibition of alloantigen formation, replace- 
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Figure 3.  The capacity of a peptide to bind 
EotE/~ molecules containing the/375s,79 s E/~ 
chain does not correlate with its capacity to 
inhibit the  3C6  IL-2 response￿9 (A)  Direct 
binding of biotinylated PCC 88-104 and bio- 
tinylated HEL 81-96 to an L cell transfectant 
expressing Et~EB molecules with the ~75~,79  ~ 
E/3  chain.  Data  are expressed as  mean net 
fluorescence  calculated as described in Materials 
and Methods￿9 (B) Effect of biotinylated PCC 
88-104 and biotinylated HEL 81-96 peptides 
on 3C6 IL-2 production induced by an L cell 
transfectant expressing EotE/~ molecules with 
the B75s,79  ~  E~ chain. Data are expressed as 
percent of the IL-2 production obtained in the 
absence of added peptide. 
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Figure 4.  High-dose inhibition 
does not account for the inhibitory 
effect of PCC 81-104 on the I1+-2 
alloresponse of 3C6 to L cells ex- 
pressing EotEB molecules with the 
/875s,79  + E8  chain.  (A)  IL-2 and 
proliferative responses of the 3C6 
clone to PCC 81-104 presented by 
an  L  cell  transfectant  expressing 
wild-type  E~E~  k molecules.  (B) 
II+-2 and proliferative responses of 
the 3C6 clone to L cells expressing 
EotEB  molecules  containing the 
~75s,79  s E~ chain in the presence 
of PCC 81-104. 
merit of agonist alloantigen with partial agonist complexes, 
nor high-dose suppression explained the inhibitory effect of 
PCC peptide on the 3C6 II+-2 alloresponse.  The effect was 
clearly  related  to  receptor engagement by  the  PCC  pep- 
tide-mutant EotEB complexes,  but  did not result  from a 
blockade of all TCR-dependent signal transduction.  Although 
it would violate the standard occupancy model of TCR stim- 
ulation, one could imagine the PCC peptide-mutant E~E~/ 
Figure  5.  The inhibitory effect of 
PCC 81-104 on IIr  alloresponses of 
3C6 is selective and does not prevent 
several other TCR-dependent activation 
events. (A) Two-color flow cytometry 
profiles of  3C6 cells  cocuhured for 24 h 
with transfected L cells expressing ei- 
ther wild-type Ec~E/~  k or EotE~ with 
the  1~75s,79  s  EB  chain.  (Left) 7D4 
(anti-IL-2R  ot  chain)  staining of G7 
(Thy-1)-positive (solid lines) and nega- 
tive (dotted lines) cells. (Right) SSC (size) 
of G7-positive cells. The EB chain of 
the EotEB molecule expressed by the L 
cell used in culture and the presence or 
absence of PCC 81-104 are indicated in 
each panel. (B) Relative change in IL- 
2Rot expression  for cells  included in the 
gate 1 subset of Thy-1  + cells in A, left, 
comparing cultures with transfectants 
expressing the B75+,79  ~  EB chain in the 
absence and presence of PCC 81-104; 
change in $8C (size) was calculated as 
change in percent of cells in gate 1 of 
A, right, comparing cultures with trans- 
fectants  expressing  the  ~75',79'  EB 
chain  in the  absence and presence of 
PCC 81-104; II+-2  and IL-3 production 
was  expressed as  relative production 
comparing cultures with transfectants 
expressing the ~75s,79 +  E~/chain in the 
absence and presence of PCC 81-104. 
(C) Reverse  transcription PCR analysis 
of RNA extracted from cocuhures of 
3C6 and transfected L cells expressing 
EotE~ molecules with the ~75',79' E~ 
chain in the absence  or presence  of PCC 
81-104 (1 #M).  (Tbp) Ethidium stain 
of PCR products;  (bottom) calculated 
relative  amounts  of  II+-2 and  11+-3 
mRNA  determined  as  described  in 
Materials and Methods. 
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Figure  6.  Antigen dose-dependent  patterns  of IL-2 and II.-3 produc- 
tion by 3C6 to peptide presented  on live or fixed L cell transfectants  ex- 
pressing  wild-type EotE~  k. Results  are expressed as percent  of the max- 
imum  II.-2 or  Ib3  response,  respectively,  obtained  with live  or fixed 
presenting cells. 
complexes acting to reduce the number of available TCR for 
alloantigen recognition by  engaging them without  con- 
tributing to signal generation. One could then explain the 
selective inhibition by PCC peptide of the IL-2 response by 
postulating that a lower level of residual second messenger 
generation in the presence of competing PCC-MHC com- 
plexes sufficed for IL-3 secretion, in comparison with that 
needed for IL-2 production. We therefore examined the rela- 
tive sensitivity of 3C6 to peptide-MHC molecule stimula- 
tion of Ib2 and IL-3 responses.  Fig.  6 shows the IL-2 and 
II.,3  responses  of 3C6  to  peptide presented by wild-type 
EotE~k-expressing APC.  Attaining  the  same fraction  of 
maximal response for IL-2 required 100-fold less peptide then 
needed for IL-3, implying that II.-3 production under these 
conditions required higher, not lower, TCtL occupancy than 
did IL-2 production. This is the opposite of what would be 
required to explain selective peptide-MHC complex inhibi- 
tion of alloantigen-driven IL-2 but not II--3 production on 
the basis of differential sensitivity to residual TCR signaling, 
because  at any level of reduced occupancy based on TCR 
blockade,  a greater reduction in IL-3 than Ib2 production 
should have been seen. 
The phenotype of TCR-dependent II.-3 production in the 
absence of 1I.-2 production by Thl clones has been previously 
reported. Thl clones stimulated by peptide-MHC complexes 
in planar membranes gave significant though subnormal IL-3 
production, whereas IL-2 production was not observed under 
these conditions (55). The defect in IL-2 production has been 
attributed to an absence of (an) essential costimulatory signal(s) 
provided by viable APC that is (are) separate and distinguish- 
able from ligand-receptor interactions that affect the occupancy 
of the TCR or its production of second messengers (56). If 
the ability of 3C6 to produce II~2 at low ligand densities 
with viable APC resulted from a potent synergy between 
TCR signaling and costimulatory signaling that did not apply 
equally to Ib3 gene activation, the differences in relative dose- 
responses for the two cytokines should be reduced or elimi- 
nated using aldehyde-fixed APC with greatly reduced levels 
of costimulatory signals. Fig. 6 shows that this was the case; 
although as previously reported (17), the absolute cytokine 
responses elicited by fixed APC were reduced >90%, the an- 
tigen concentration needed for half-maximal II.-3 responses 
was only slightly increased (,o3 x) compared with that needed 
with viable APC, whereas the dose needed for half-maximal 
IL-2 production increased close to 100-fold to approach that 
required for II.-3. 
Evidence for a Relationship between Costimulatory Signaling 
and Selective Inhibition of II.:2 Responses by Cytochrome Pep- 
tide.  These data on cytokine responses to viable and fixed 
cells suggest that the selective inhibition by PCC-mutant 
EotEB complexes of alloantigen-stimulated IL-2 but not IL-3 
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Figure 7.  PCC 81-104 does not 
inhibit the IL-2 response and can in- 
crease the Ib3 response of the C6E1 
hybfidoma to L cell transfectants ex- 
pressing EotEB molecules with the 
~75',79'  EB  chain.  (A)  II.-2 and 
II.-3  responses  of  the  C6E1  hy- 
bridoma  to  PCC  81-104  peptide 
presented by L ceils expressing wild- 
type  Ec~E/~  k molecules.  Data  are 
expressed  as  percent  of maximal 
stimulation of II_.2 and 1I.-3, respec- 
tively. (B) Ib2 and Ib3 responses 
of the  C6E1  hybridoma  to PCC 
81-104 peptide presented by L cells 
expressing  E~EB molecules  with 
the/~75s,79  ~  E~ chain. Data are ex- 
pressed as percent  of the response 
obtained  in  the  absence of PCC 
81-104 peptide. 
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of, or response to, costimulation  in the cultures. The L cell 
transfectant used in the experiment shown in Fig. 6 constit- 
utively expresses B7 (57, and our unpublished observations), 
a ligand for the CD28 costimulatory pathway, and the ca- 
pacity to observe low but detectable I1:2 production using 
these APC after fixation appears to relate to a low level of 
residual costimulation mediated by preexisting B7 present on 
these fixed cells. However, experiments with purified pep- 
tide-MHC complexes in planar membranes have shown that 
Thl clones do not produce I1:2 in response to peptide-MHC 
molecule ligands in the total absence of costimulatory signals 
(55). Thus, we could not test this hypothesis concerning the 
locus of the peptide inhibitory effect by examining 3C6 I1:2 
production in response to alloantigen  in the complete ab- 
sence of costimulation.  However, T cell hybridomas do pro- 
duce II:2 in the absence of costimulatory signals, such as in 
response to peptide-MHC complexes in planar membranes 
(58). We therefore examined the effect of added PCC pep- 
tide on the mutant EotE/3 alloresponse of a T cell hybridoma 
bearing the same TCR as 3C6. This hybrid was derived by 
fusion of a TCR. chain-negative T lymphoma cell with the 
3C6 clone and it has a peptide and alloantigen response profile 
indistinguishable  from the 3C6 clone (not shown). 
Evidence that costimulation-related  signals do not play a 
major role in I1:2 production by the hybridoma comes from 
a dose-response analysis comparing I1:2 and I1:3 generation 
(Fig. 7 A). In the presence of viable APC, the hybridoma 
did not exhibit the difference in I1:2 and I1:3 dose-responses 
characteristic of the 3C6 Thl clone, but instead responded 
almost precisely as the clone did to fixed APC lacking al- 
most all costimulatory activity. This is consistent with the 
hypothesis that the difference in the cytokine dose-responses 
seen using the clone reflected the asymmetric contribution 
of costimulation to the I1:2 response of normal T cells, and 
suggested that if the inhibitory effect of PCC peptide on the 
alloresponse of the clone were due to interference with ex- 
ogenously provided costimulation, such inhibition should not 
be seen  with the hybridoma. In agreement with this predic- 
tion,  Fig.  7  B  shows  that  the  hybridoma's  alloantigen- 
stimulated  I1:2 response was not decreased by addition  of 
PCC peptide. 
These data also indicate  that the PCC peptide-mutant 
MHC class II complexes are not pure antagonists of, but ac- 
tually weak agonists for, TCK signal generation, because at 
high antigen concentrations they could dearly elicit an effector 
response from the hybridoma (increased I1:3 production). 
Given the slight dose-response advantage seen for I1:2 vs. I1:3 
production in Fig. 7 A, it was somewhat surprising that we 
did not observe a similar increase in I1:2 secretion at these 
antigen concentrations. This result may be explained  by gener- 
ation of qualitatively different signals upon TCR engagement 
of  wild-type MHC-PCC peptide vs. mutant MHC-PCC pep- 
tide ligand,  which in the latter case is inadequate to evoke 
I1:2 responses. Alternatively, although costimulation is not 
required for I1:2 production by T hybridomas, it can modestly 
increase such responses (our unpublished  observations),  a 
phenomenon consistent with the slight dose-response advan- 
tage seen  for I1:2 compared with I1:3. In the presence of pep- 
tide-mutant MHC molecule complexes, a balance between 
weak receptor signaling and simultaneous inhibition of the 
small costimulation effect would then explain the failure to 
see an increase in II,-2 production in a fashion fully concor- 
dant with the results obtained  using the 3C6 clone. 
Effects of Anti-CD28 Antibody.  Interaction  of the CD28 
molecule on T cells with the B7 membrane protein on APC 
appears to activate a major costimulatory pathway involved 
in regulating I1:2 production (11-13, 20-22).  Antibody to 
the CD28 molecule on mouse or human T cells can modu- 
late the cytokine response of such cells to TCR stimulation 
(36, 59,  60),  presumably by altering  delivery of a critical 
costimulatory signal. Because of the above observations sug- 
gesting that the PCC-induced downregulation of I1:2 re- 
sponses was related to the special contribution of costimula- 
tion to I1:2 production, we examined the role of CD28 in 
I1_,2 responses of the 3C6  clone  and  the possibility  that 
antibody-mediated activation of the CD28 signaling pathway 
might counteract the inhibitory effect of the peptide-mu- 
tant MHC complexes. 
Fig. 8 A  shows that inclusion of soluble anti-CD28  in a 
cocuhure of 3C6 and the allostimulatory L cell transfectant 
inhibited  I1:2 production almost  completely, without de- 
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Figure  8.  Antibody crosslinking  of CD28 on the 3C6 clone does not 
prevent selective PCC 81-104-mediated  inhibition of IL-2 alloresponses. 
(A) IL-2 and IIr  responses of the 3C6 clone in the absence or presence 
of anti-CD28 mAb (1:250 dilution of ascites) to an L cell transfectant  ex- 
pressing E~E3 molecules containing the ~75',79,  E/~ chain. Data are ex- 
pressed as percent of the response obtained in the absence of the anti-CD28 
antibody. (B) Effect of anti-CD28 antibody-mediated  crosslinking on the 
IL-2 and IL-3 responses of 3C6 to an L cell expressing E~E3 molecules 
with  the  B75~,79  '  EB  chain  in  the  presence  of PCC  81-104  peptide 
(1/xM).  Data are expressed as percent of the response obtained in the ab- 
sence of both the anti-CD28 antibody  and the PCC peptide. 
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effect of soluble anti-CD28 on IL-2 secretion in response to 
alloantigen (59) and replicated the phenotype seen when PCC 
peptide was added to similar cultures. The ability of soluble 
anti-CD28 to inhibit IL-2 responses by the 3C6 clone sug- 
gests a critical contribution of this molecule to costimula- 
tion of IL-2 production, presumably via interaction with the 
B7 surface protein present on the transfected  L cells. Anti- 
Ig-mediated crosslinking could overcome the inhibitory effect 
of soluble anti-CD28 on IL-2 responses  of 3C6 in the ab- 
sence of PCC peptide. The increase in IL-3 production seen 
using crosslinked anti-CD28 antibody is consistent with the 
known ability of costimulation to augment this response 
without being required for it, and provides additional evi- 
dence for the efficacy  of the crosslinking procedure in activating 
the  CD28  pathway.  Nevertheless,  even  though  CD28- 
dependent signaling appeared necessary for IL-2 production 
by 3C6 cells, antibody-dependent stimulation of this pathway 
did not reverse the inhibition of IL-2 secretion mediated by 
PCC peptide addition (Fig. 8 B). These results suggest that 
peptide-mediated inhibition of IL-2 secretion either involves 
interference with effective CD28 costimulatory signal trans- 
duction at a site within the T cell or the disruption of a cru- 
cial costimulatory pathway distinct from that evoked by CD28 
aggregation (see Discussion). 
Discussion 
The results reported here describe a new class of TCK c~/3 
ligands that might best be called mixed agonists/antagonists, 
whose interaction with TCRs results in differential stimula- 
tion or suppression of various  effector functions. Previous 
studies (55, 61) have shown that it is possible to separate effector 
activities  of both CD4 § and CD8 + T cells into those that 
do (IL-2 secretion)  and do not (IL-3 secretion,  cell killing) 
show a nearly absolute requirement for costimulatory signals. 
In these prior reports, the dichotomy was achieved by ma- 
nipulation of the potential of the APC to provide costimula- 
tion, and did not vary according to the ligand used for TCR 
engagement. The present study shows that changing the struc- 
ture of the TCR ligand by even a single amino acid can inter- 
fere with the elicitation of costimulation-dependent effector 
responses to ligand presented by a physiologically intact APC. 
Although we have mutated the MHC class II molecule in 
the present case, current understanding of T cell recognition 
implies that a similar effect could be mediated by appropriate 
changes in the peptide. This would be in accord with the 
results  of Evavold and Allen (28),  who found that a pep- 
tide-MHC complex differing from the wild type in a single 
residue of the peptide lost the capacity to induce proliferative 
responses by a Th2 clone, while remaining able to evoke IL-4 
production. 
However, in marked contrast to the results of these inves- 
tigators, the mutant EotE3-peptide ligand studied here did 
not simply fail to elicit certain T cell responses, but actively 
interfered with some but not other differentiation events medi- 
ated by TCR occupancy with typical agonist ligand. 11,2 secre- 
tion was decreased without substantial interference with the 
development of signals in the T cell that suffice for induction 
of IL-3 secretion, IL-2Rot upregulation, and size enlargement 
responses. A peptide able to bind to the mutant Ec~E3 mole- 
cule but unrelated to the 3C6 receptor specificity did not have 
any significant inhibitory function. If the loss of IL-2 response 
were due simply to loading alloantigenic mutant Eo~EB mol- 
ecules (either empty or containing some naturally processed 
antigen) with the cytochrome peptide, eliminating these fully 
stimulatory ligands, and producing partial agonist complexes 
able to trigger Ib3 but not Ib2 responses, the unrelated HEL 
peptide should have inhibited both responses as a result of 
such alloantigen replacement. Because this was not observed, 
the mechanism of IL-2 inhibition cannot be simple removal 
of the stimulatory ligand from the culture. 
The selective blockade of II,-2 production seen here in the 
face of persistent TCR signaling differs markedly from the 
results reported by De Magistris et al. (62). These authors 
observed  a  similar  dominant interference  by variant  pep- 
tide-MHC complexes with agonist ligand-induced IL-2 re- 
sponses. However, they concluded that these inhibitory com- 
plexes were pure TCR antagonists, lacking the capacity to 
generate any intracellular  signals themselves  and acting by 
simple receptor competition to completely block all signal 
generation by available agonist complexes. There may well 
be two distinct classes of inhibitory peptide-MHC complexes, 
one with pure antagonist activity and the other with mixed 
agonist/antagonist potential, that interfere with T  cell re- 
sponses by distinct means. The former would prevent intra- 
cellular messenger generation in the T cell by removing TCRs 
from the functional pool, thus allowing no effector responses. 
The latter would interfere with certain effector activities based 
on qualitative differences in requirements for intraceUular sig- 
naling, possibly related to the costimulation dependence of 
the functions analyzed.  However,  only Ib2 responses were 
measured in the simultaneous presence of agonist and inhibi- 
tory peptides by De Magistris et al. (62). It is therefore pos- 
sible that the conclusion we reach here that the defective re- 
sponse does not result from simple TCR blockade, but rather 
from a qualitative  difference in signaling, may also apply to 
the peptide-MHC combinations studied by these other in- 
vestigators. 
Several observations, including the selective  inhibitory effect 
of peptide on IL-2 production, the dramatic effect of fixation 
on IL-2 but not Ib3 dose-response relationships, and the failure 
of peptide to inhibit ID2 production by a T cell hybridoma, 
all suggested that the peptide-mutant MHC complexes might 
be acting to interfere with the production of, or response 
to, costimulatory signals. Numerous reports indicate that the 
interaction of CD28 on responding T cells with B7 on APC 
provides important signals for the generation of high-level 
I1,-2 production (11-13, 20-22). Soluble anti-CD28 antibody 
affected the 3C6 response to alloantigen in a manner similar 
to inclusion ofPCC peptide, in that IL-3 responses were main- 
tained in the face of inhibition of IL-2 production. This re- 
sult is also consistent with a model in which the inhibitory 
effect of PCC peptide on alloresponses is related to alteration 
1055  Racioppi et al. in costimulatory signalling. Crosslinking the anti-CD28 an- 
tibody reversed the inhibition of alloresponses by the soluble 
CD28, in agreement with the previous report of Damle et 
al. (59), and this maneuver increased IL-3 responses, indicating 
effective stimulation of the CD28 pathway.  However,  such 
crosslinking of the CD28 molecules on 3C6 cells did not 
prevent the inhibition of IL-2 production mediated by ex- 
posure to PCC-mutant MHC class II complexes. These ob- 
servations  imply that CD28-B7 interaction may be neces- 
sary but not sufficient for Ib2 responses under the present 
conditions. It is possible that the intracellular  signals deliv- 
ered through CD28 are not effective when the 3C6 TCR 
is engaged with the PCC peptide-mutant Ec~E/~ complexes, 
implying the generation of dominant-negative intracellular 
messengers by the mixed agonist/antagonist complexes. This 
hypothesis is consistent with preliminary data on the ability 
of peptide-MHC complexes to inhibit IL-2 production by 
3C6 in the presence of PMA and ionophore (L.  Racioppi 
and R. N. Germain, unpublished observations),  The effects 
of such interfering signals would have to be gene or tran- 
script specific, as I1.4 production was actually increased under 
the same conditions. Alternatively,  costimulatory receptor- 
ligand interactions distinct from CD28-B7 may be impor- 
tant. The heat-stable antigen (23) has recently been suggested 
as another APC-expressed molecule regulating IL-2 produc- 
tion (19), and experiments are in progress to evaluate the rela- 
tionship of this costimulatory pathway to selective peptide- 
MHC molecule-mediated inhibition of Ib2 responses. 
Exploration of the basis for the ability of PCC peptide 
to inhibit alloresponses by the 3C6 clone led to additional 
insights concerning T cell activation and signaling.  Careful 
dose-response titrations showed that distinct effector activi- 
ties had grossly different quantitative thresholds for elicita- 
tion. In particular,  100-fold less peptide-MHC ligand was 
needed to evoke II,-2 than IL-3 responses in the presence of 
wild-type Ec~E3  k. This difference appeared to be due to the 
more potent synergy of costimulation with TCR.-dependent 
induction of IL-2 secretion. An appealing explanation of this 
effect comes from considering downstream signaling events. 
Ultimately, the readout of surface receptor engagement is 
gene activation mediated by various transcription factor com- 
plexes (63). An emergent theme of promoter function is the 
role of a complex array of short motifs acted upon by a number 
of distinct constitutive and regulated factors, both positive 
and negative, in determining gene activity (64). Evidence exists 
that costimulation results in the enhanced function of tran- 
scription  factors  distinct  from  those  invoked  by  TCR- 
dependent signals alone (65). If the gene of interest can have 
its transcriptional activity markedly increased via a costimu- 
lation-dependent factor, the consequent effector activity will 
be very costimulation sensitive, and may show a decreased 
requirement for TCR signals due to amplification of a small 
amount of these latter signals. Alternatively, the apparent gene 
specificity  might  be  mediated by  selective  costimulator- 
dependent changes in mRNA lifetime. Either model is fully 
consistent with the relationship between IL-2 and IL-3 re- 
sponses observed here using viable vs. fixed APC. This argues 
that qualitative  differences in effector function that depend 
on the mix and proportion of cytokines produced by a T 
cell may be influenced in a nonlinear way by the balance be- 
tween TCR and costimulation signaling. This will not only 
vary according to the APC and T  cells involved, but also 
in accord with the properties of the ligand, as shown here. 
This model can explain the data reported by Soloway et al. 
(66) in which alterations  in peptide ligand or dose affected 
the quality of the immune response, and also the results of 
Murray et al. (67) in which a change in qualitative  effector 
activity accompanied alteration in ligand concentration. 
The molecular mechanism by which a modified receptor 
ligand can change integration of TCR and costimulatory sig- 
naling is unclear. A simple view of the occupancy model of 
T  cell activation would argue that independent of affinity, 
any ligand able to engage the receptor would contribute in 
a positive sense to development of intracellular  signals. This 
is because the presence of ligand of any quality would always 
serve to increase the steady-state number of occupied receptors 
and thus the number of aggregated (signaling)  TCR com- 
plexes. Furthermore, no matter what the affinity of the in- 
teraction with the TCR, ligands that do not reduce the avail- 
able number of agonist complexes on the APC itself should 
not interfere with T cell activation by the good ligand. This 
is because the poor ligand must at equilibrium itself occupy 
each TCR that is prevented from interacting with the good 
(agonist) ligand (25). Therefore, although the nature of the 
ligand occupying the TCR will change as more and more 
poor ligand is added, the total number of occupied receptors 
will not be altered and the same aggregation-dependent signal 
generation should occur. As this does not fit the present data, 
a more complex model must be considered. 
TCR signal transduction requires participation of a number 
of membrane components that are not in tight or permanent 
association. Interaction among these components results from 
ligand binding by the TCR and other molecules, such as the 
CD4 or CD8 coreceptors (26, 68). In this regard, formation 
of an active signaling complex by the T cell is like associa- 
tion of univalent growth factor receptors that need to dimerize 
to signal (69).  Conformational changes induced by ligand 
binding have been suggested to play a role of growth factor 
association and subsequent signaling, and the pattern of second 
messengers  generated by TCR occupancy could vary with 
the quality rather than binding affinity of the ligand on such 
a conformation-dependent  basis. In the T cell case, however, 
the TCR seems to have a substantially lower affinity for its 
ligand than a typical growth factor receptor for its (70, 71). 
Ligand-engaged TCRs therefore exist  as a pool of loosely 
associated complexes in the same membrane region, with rapid 
dissociation and reassociation  among components. Reduc- 
tion in effective binding affinity for a specific ligand could 
thus result in an inability to maintain an adequate local pool 
of engaged complexes, and TCR/TCR or TCR/coreceptor 
(CD4, CDS) association might not persist for the time needed 
for full development of cytosolic muhiprotein assemblies in- 
volved in signal propagation (26,  72).  This kinetic model 
of TCR signaling is very similar in principle to the explana- 
1056  TCR Ligands with Mixed Agonist/Antagonist  Properties tion put forth by Metcalf and Klinman (73) to explain why 
modest differences in B cell Ig receptor affinity for structur- 
ally related haptens resulted in an all-or-nothing difference 
in signaling function that could not be compensated for by 
appropriate increases  in ligand concentration. 
Generation of only a subset of TCR-dependent intracel- 
lular signals  due to either conformation- or affinity-related 
effects of altered ligand structure could thus result in selec- 
tive gene activation. The production of excess negative medi- 
ators by the PCC peptide-mutant EotE/8 molecules that could 
inhibit CD28-dependent intracellular signaling might explain 
why CD28  crosslinking could not overcome the peptide- 
induced inhibition of IL-2 production. Alternatively, even with 
decreased TCR-ligand affinity,  the incomplete agonist we 
have studied might generate a normal pattern ofintracellular 
messengers in the T  cell itself.  There is accumulating evi- 
dence that the costimulatory function of many APC is ini- 
tially low and needs to be upregulated during T  cell-APC 
interaction (12, 57). If so, then a reduced TCR-ligand affinity 
might interfere with aggregation-based signaling (perhaps 
via the MHC  class II molecules of the APC),  preventing 
needed costimulator upregulation. This would lead to intra- 
cellular T cell signaling under conditions in which APC second 
messenger generation, and hence, APC costimulatory activity, 
is deficient. Irrespective of whether the site of defective sig- 
naling is the T cell or the APC, the ability of relatively small 
numbers of incomplete agonist complexes to interfere with 
responses in the presence of complete agonist ligand implies 
that introduction of ineffective TCR-ligand complexes into 
the forming signaling assemblies at the T celI-APC interface 
interferes in a nonlinear way with signal generation. 
Our data on different thresholds for distinct T cell differen- 
tiation events and on the ability of incomplete agonists to 
dominantly interfere with T  cell effector function have im- 
plications for understanding intrathymic T cell development 
and for the creation of new approaches to autoimmune dis- 
ease treatment and vaccine design.  Exposure of immature 
thymocytes to both TCR and costimulatory signals may be 
responsible for intrathymic deletion (74). If some ligands can 
generate intracellular signals  in T  cells adequate for certain 
gene activation events without permitting effective costimu- 
lation, these would constitute ligands with the proper char- 
acteristics for positive selection of thymocytes without sub- 
sequent negative selection. In addition, the marked difference 
in threshold stimulation of different effector activities seen 
in comparing IL-2 vs. IL-3 secretion would suggest that in 
and of itself low level receptor occupancy could evoke differen- 
tiation without deletion in developing thymocytes, just as 
it would stimulate ILo2 without Ib3 production in mature 
cells. This suggestion is in full accord with the recent report 
of Robey et al.  (75)  on the effect of changing CD8 levels 
on thymic selection. 
The present results also suggest an alternative explanation 
for some instances of immune downregulation reported upon 
coimmunization with related peptides that have been previ- 
ously ascribed to competition for peptide binding to MHC 
molecules (76, 77).  Because T  cell signaling in the absence 
of costimulation frequently leads to a state of unresponsive- 
ness termed anergy (78),  not only would a properly altered 
self-peptide with incomplete agonist properties potentially 
be able to block ongoing autoimmune T  effector activity, 
as might a true MHC blocking peptide, but administration 
of antigens generating mixed agonist/antagonist complexes 
might lead to a lasting decrease in autoimmune disease due 
to anergy induction among the self-reactive T cells. Finally, 
the  split  in  cytokine production  seen  with  such  mixed 
agonist/antagonist complexes might also be used to deviate 
immune responses after vaccination away from those that 
sometime potentiate disease upon subsequent infection and 
towards those that are highly protective. Additional study 
of this novel class of TCR ligand is thus likely to produce 
new insights in both basic T cell biology and applied immu- 
nology. 
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